Raymond James Financial Inc. Purchases Shares of 1,112,275 ADMA Biologics, Inc. (NASDAQ:ADMA)

Raymond James Financial Inc. purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,112,275 shares of the biotechnology company's stock, valued at approximately $19,076,000. Raymond James Financial Inc. owned about 0.47% of ADMA Biologics at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC increased its position in ADMA Biologics by 192.2% in the 3rd quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock valued at $10,567,000 after acquiring an additional 347,692 shares during the period. Franklin Resources Inc. raised its position in ADMA Biologics by 19.4% during the 3rd quarter. Franklin Resources Inc. now owns 167,644 shares of the biotechnology company's stock worth $3,351,000 after purchasing an additional 27,180 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in ADMA Biologics during the 3rd quarter worth about $368,000. Lord Abbett & CO. LLC bought a new stake in shares of ADMA Biologics in the 3rd quarter valued at about $61,858,000. Finally, Principal Financial Group Inc. increased its stake in shares of ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock valued at $23,872,000 after buying an additional 1,059,394 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Trading Down 1.6 %

Shares of NASDAQ:ADMA traded down $0.37 during midday trading on Friday, reaching $21.97. The company's stock had a trading volume of 773,183 shares, compared to its average volume of 2,934,400. ADMA Biologics, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a 50 day moving average price of $18.68 and a two-hundred day moving average price of $18.27. The firm has a market capitalization of $5.19 billion, a price-to-earnings ratio of 78.45 and a beta of 0.53.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.